Seegene MIDDLE EAST participated in MEDLAB 2018, the specialized world-class exhibition of laboratory medicine that was held in Dubai, United Arab Emirates (UAE) from February 5th to 8th, 2018.

MEDLAB is an exhibition that covers issues of medical devices, diagnostics technology, laboratory management, health care, clinical chemistry, molecular diagnostics and latest trend of laboratory medicine, and this year, more than 25,000 people and 700 companies participated. And in this year’s event, the latest technology and study cases of respiratory diseases in clinical management was dealt importantly in the symposium and workshop.

Seegene MIDDLE EAST- a subsidiary of Seegene Inc. - introduced All-in-One platform that is a consolidation platform which can be applied a broad molecular diagnostic test menu of infectious diseases including respiratory, gastrointestinal diseases and women’s health. Moreover, they presented newly launched and upcoming products in 2018 which also can be applied in the platform.

In particular, through a special space where the participants can experience the All-in-One platform, they showed the possibility of various kinds of molecular diagnoses with minimum manpower and space. As a result, they could start an aggressive marketing to customers of middle- to large-sized hospitals where considering to adopt molecular diagnostics and expand test menu.

The president of Seegene MIDDLE EAST said, “To attract the rapidly changing Middle East medical market, a continuous monitoring of the general market status and trend change are required, and MEDLAB is the most appropriate opportunity to satisfy such requirements. Seegene has raised the value of company brand as a representative of multiplex molecular diagnostics through continuous participation of MEDLAB for the last eight years. Also, visible results such as expansion of distribution channels to the Middle East countries including UAE, Saudi Arabia, Egypt etc. in which the demand of in vitro diagnostics is expanding and North Africa region are being made.” Furthermore, the president added, “It is expected that All-in-One platform reduces the difficulty and repulsion of adopting molecular diagnostic test, and at the same time, not only the best-selling infectious disease diagnostic products including respiratory virus and bacteria tests and sexually transmitted disease, but also the products that will be launched soon will lead to rapid sales growth.”